Display options
Cite
Mozafari N, Shamsizadeh A, Fatemi I, et al. CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease. Iran J Basic Med Sci. 2018;21(7):724-730doi: 10.22038/IJBMS.2018.28544.6934.
Mozafari, N., Shamsizadeh, A., Fatemi, I., Allahtavakoli, M., Moghadam-Ahmadi, A., Kaviani, E., & Kaeidi, A. (2018). CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease. Iranian journal of basic medical sciences, 21(7), 724-730. https://doi.org/10.22038/IJBMS.2018.28544.6934
Mozafari, Nazanin, et al. "CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease." Iranian journal of basic medical sciences vol. 21,7 (2018): 724-730. doi: https://doi.org/10.22038/IJBMS.2018.28544.6934
Mozafari N, Shamsizadeh A, Fatemi I, Allahtavakoli M, Moghadam-Ahmadi A, Kaviani E, Kaeidi A. CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease. Iran J Basic Med Sci. 2018 Jul;21(7):724-730. doi: 10.22038/IJBMS.2018.28544.6934. PMID: 30140412; PMCID: PMC6098965.
Copy Download .nbib Format: NLM
Share it on

Iran J Basic Med Sci. 2018 Jul;21(7):724-730. doi: 10.22038/IJBMS.2018.28544.6934.

CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease.

Iranian journal of basic medical sciences

Nazanin Mozafari, Ali Shamsizadeh, Iman Fatemi, Mohammad Allahtavakoli, Amir Moghadam-Ahmadi, Elham Kaviani, Ayat Kaeidi

Affiliations

  1. Physiology-Pharmacology Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  2. Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  3. School of Medicine and Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

PMID: 30140412 PMCID: PMC6098965 DOI: 10.22038/IJBMS.2018.28544.6934

Abstract

OBJECTIVES: Growing evidence suggests that dysfunction of the glutamatergic system and α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) receptors are involved in pathology of Alzheimer's disease (AD). Because AMPA receptors play a key role in plasticity synaptic regulation, positive modulation of these receptors may rescue the cognitive deficits in the AD. The aim of this study was to explore the effect of CX691, a specific positive allosteric modulator of the AMPA-type glutamate receptors (Ampakine), on spatial learning and memory in a rat model of AD.

MATERIALS AND METHODS: For induction of AD, amyloid-beta 1-42 (Aβ1-42) was microinjected into the hippocampus of male Wistar rats (250-300 g). The Morris water maze (MWM) test was used to evaluate the effect of CX691 (0.03 and 0.3 mg/kg, twice a day for 10 days, orally) on spatial learning and memory of rats. In order to evaluate the protein expression of brain-derived neurotrophic factor (BDNF) in hippocampus tissue, ELISA test was used.

RESULTS: The obtained data showed that treatment with CX691 (0.3 mg/kg) improves the impairment of spatial learning and memory in AD rats. Also, treatment with CX691 (0.3 mg/kg), increased the BDNF protein level in hippocampus tissue of AD rats compared to non-treated animals.

CONCLUSION: The CX691 can improve the BDNF protein expression as well as spatial performance of learning and memory in AD rats.

Keywords: AMPA receptors; Alzheimer’s disease; BDNF; CX691; Memory; Rat

Conflict of interest statement

The authors declare no conflict of interest relevant to this article.

References

  1. J Neurosci. 2009 Jul 8;29(27):8688-97 - PubMed
  2. Trends Neurosci. 2006 Oct;29(10):554-62 - PubMed
  3. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6526-E6534 - PubMed
  4. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4906-11 - PubMed
  5. Synapse. 1993 Dec;15(4):326-9 - PubMed
  6. J Neurosci. 1995 Dec;15(12):8023-30 - PubMed
  7. PLoS One. 2015 Apr 07;10(4):e0122415 - PubMed
  8. Handb Exp Pharmacol. 2014;220:223-50 - PubMed
  9. Eur J Pharmacol. 2007 Apr 30;561(1-3):23-31 - PubMed
  10. Biochem Pharmacol. 2014 Apr 15;88(4):661-70 - PubMed
  11. Nat Med. 2009 Mar;15(3):331-7 - PubMed
  12. Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):821-8 - PubMed
  13. Eur J Neurosci. 2012 Jun;35(12):1908-16 - PubMed
  14. Psychopharmacology (Berl). 2009 Jan;202(1-3):343-54 - PubMed
  15. Trends Neurosci. 2017 Jun;40(6):347-357 - PubMed
  16. Neuropharmacology. 2014 Jan;76 Pt C:696-708 - PubMed
  17. Brain Res. 1994 Feb 28;638(1-2):343-6 - PubMed
  18. Psychopharmacology (Berl). 2012 May;221(1):115-31 - PubMed
  19. J Neurosci. 2000 Jan 1;20(1):8-21 - PubMed
  20. Neuron. 2006 Dec 7;52(5):831-43 - PubMed
  21. Exp Neurol. 2008 Mar;210(1):164-71 - PubMed
  22. Annu Rev Neurosci. 2002;25:103-26 - PubMed
  23. Brain Res Brain Res Rev. 1998 Jun;27(1):1-39 - PubMed
  24. J Neural Transm (Vienna). 2014 Aug;121(8):799-817 - PubMed
  25. Neuron. 1991 Nov;7(5):695-702 - PubMed
  26. PLoS One. 2013 Oct 04;8(10):e75786 - PubMed
  27. J Neurosci. 2013 Sep 25;33(39):15596-602 - PubMed
  28. Eur J Pharmacol. 2000 Aug 4;401(2):205-12 - PubMed
  29. J Neurosci. 1998 Apr 1;18(7):2740-7 - PubMed
  30. Neural Plast. 2016;2016:3204519 - PubMed
  31. Arch Neurol. 2000 Jun;57(6):846-51 - PubMed
  32. J Neurosci. 2007 Mar 14;27(11):2866-75 - PubMed
  33. Neuropharmacology. 2001 Jun;40(8):1019-27 - PubMed
  34. J Cell Mol Med. 2008 Jan-Feb;12(1):38-55 - PubMed
  35. Neuron. 2003 Mar 27;37(6):925-37 - PubMed
  36. Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94 - PubMed
  37. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11158-62 - PubMed
  38. J Pharmacol Exp Ther. 1999 Apr;289(1):392-7 - PubMed
  39. Neurosci Lett. 1995 Feb 17;186(2-3):153-6 - PubMed
  40. Prog Neurobiol. 2001 Jan;63(1):71-124 - PubMed
  41. Neurobiol Dis. 2017 Jan;97(Pt B):114-118 - PubMed
  42. Neuropsychopharmacology. 2007 Jun;32(6):1272-83 - PubMed
  43. Trends Neurosci. 2000 Dec;23(12):639-45 - PubMed
  44. Nat Rev Drug Discov. 2011 Mar;10(3):209-19 - PubMed
  45. Curr Opin Pharmacol. 2015 Feb;20:46-53 - PubMed
  46. Trends Neurosci. 1994 Nov;17(11):490-6 - PubMed
  47. Neurobiol Dis. 1998 Aug;5(2):67-80 - PubMed

Publication Types